Hepatocellular Carcinoma Screening and Diagnosis

Morris Sherman; Massimo Colombo

doi:10.1055/s-0034-1394139

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2014; 34(04): 389-397
DOI: 10.1055/s-0034-1394139

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatocellular Carcinoma Screening and Diagnosis

Morris Sherman

¹Department of Medicine, University of Toronto, Toronto, Ontario, Canada

,

Massimo Colombo

²Department of Liver, Kidney, Lung and Bone Marrow Units and Organ Transplant, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Università degli Studi di Milano, Milano, Italy

› Author Affiliations

Abstract

All the major liver disease societies have recommended screening for hepatocellular carcinoma (HCC). The target population for HCC screening has been defined by cost-efficacy analyses and by risk scores. Risk scores have been developed for patients with hepatitis B, regardless of the presence of cirrhosis, and for other patients with cirrhosis. Screening is with ultrasound; however, in Asia biomarkers are also used. The additional value of biomarkers has not been demonstrated. The ideal screening interval is 6 months; in Japan shorter intervals are used. Screening detects small lesions that require confirmation of HCC. There are radiological criteria that help determine whether a biopsy is necessary. Special stains can determine whether a lesion that closely resembles normal or dysplastic tissue is HCC. All these tools should be used in the management of patients undergoing HCC screening.

Keywords

hepatocellular carcinoma - cost-efficacy analysis - alpha fetoprotein - risk scores

Full Text

References

References
1 Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
2 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4) 908-943
3 Omata M, Lesmana LA, Tateishi R , et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4 (2) 439-474
4 Ziol M, Handra-Luca A, Kettaneh A , et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41 (1) 48-54
5 Castéra L, Vergniol J, Foucher J , et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2) 343-350
6 Yeh YP, Hu TH, Cho PY , et al; Changhua Community-Based Abdominal Ultrasonography Screening Group. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology 2014; 59 (5) 1840-1849
7 Bruix J, Sherman M ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5) 1208-1236
8 Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57 (1) 84-90
9 Gui HL, Wang H, Yang YH , et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 2010; 17 (Suppl. 01) 44-50
10 Chen CJ, Yang HI, Su J , et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1) 65-73
11 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3) 678-686
12 Tang B, Kruger WD, Chen G , et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72 (1) 35-40
13 Mendy ME, Welzel T, Lesi OA , et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2010; 17 (2) 115-122
14 Yang HI, Sherman M, Su J , et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28 (14) 2437-2444
15 Yang HI, Yuen MF, Chan HL , et al; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12 (6) 568-574
16 Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther 2013; 37 (2) 243-251
17 Wong VW, Chan SL, Mo F , et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28 (10) 1660-1665
18 Yuen MF, Tanaka Y, Fong DY , et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50 (1) 80-88
19 Lok AS, Seeff LB, Morgan TR , et al; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136 (1) 138-148
20 Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012; 156 (12) 841-847 , W295
21 Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60 (3) 612-617
22 Caballería L, Parés A, Castells A, Ginés A, Bru C, Rodés J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96 (4) 1160-1163
23 Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. Cancer 2014; [Epub ahead of print]
24 Nouso K, Tanaka H, Uematsu S , et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008; 23 (3) 437-444
25 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19 (11) 1159-1172
26 Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98 (3) 679-690
27 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6 (12) 1418-1424
28 Cucchetti A, Trevisani F, Cescon M , et al; Italian Liver Cancer (ITA.LI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian liver cancer population. J Hepatol 2012; 56 (5) 1089-1096
29 Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101 (4) 422-434
30 Thompson Coon J, Rogers G, Hewson P , et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11 (34) 1-206
31 Saab S, Ly D, Nieto J , et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9 (7) 672-681
32 Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010; 16 (10) 1186-1194
33 Thompson Coon J, Rogers G, Hewson P , et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008; 98 (7) 1166-1175
34 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3 (1) 75-84
35 Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992; 7 (5) 463-468
36 Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc 2010; 109 (1) 39-55
37 Singal A, Volk ML, Waljee A , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30 (1) 37-47
38 Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography — a randomised study. Aliment Pharmacol Ther 2013; 38 (3) 303-312
39 Trinchet JC, Chaffaut C, Bourcier V , et al; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54 (6) 1987-1997
40 Wang JH, Chang KC, Kee KM , et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol 2013; 108 (3) 416-424
41 Vilana R, Forner A, Bianchi L , et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51 (6) 2020-2029
42 Galassi M, Iavarone M, Rossi S , et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 2013; 33 (5) 771-779
43 Liver Imaging Reporting and Data System (LI-RADS). Available at: http://www.acr.org/Quality-Safety/Resources/LIRADS . Accessed September 12, 2014
44 Manini MA, Sangiovanni A, Fornari F , et al; Study Participants. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 2014; 60 (5) 995-1001
45 Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25 (2) 133-142
46 Di Tommaso L, Destro A, Fabbris V , et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011; 53 (5) 1549-1557
47 Tremosini S, Forner A, Boix L , et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012; 61 (10) 1481-1487
48 Papak J, Pasha AS, O'Neil M , et al. Screening for hepatocellular cancer in chronic liver disease: a systematic review. Ann Intern Med 2014; 161 (4) 261-269
49 Chen JG, Parkin DM, Chen QG , et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10 (4) 204-209
50 Yang B, Zhang B, Xu Y , et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123 (6) 357-360
51 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (7) 417-422
52 Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012; 156 (5) 387-389
53 Sherman M, Bruix J, Porayko M, Tran T ; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56 (3) 793-796
54 Cucchetti A, Trevisani F, Pecorelli A , et al; Italian Liver Cancer (ITA.LI.CA) group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol 2014; 61 (2) 333-341